Results 101 to 110 of about 158,299 (299)

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay   +5 more
wiley   +1 more source

Scientific Rationale for Waiving Clinical Efficacy Testing of Biosimilars

open access: yesDrug Design, Development and Therapy, 2022
Sarfaraz Niazi Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois, Chicago, IL, USACorrespondence: Sarfaraz Niazi, Email niazi@niazi.comAbstract: After 18 years and the administration of billions of doses, there is little ...
Niazi S
doaj  

EMA [PDF]

open access: yesTechniques & culture, 2011
openaire   +2 more sources

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Ambulanssin oikeaoppinen sisäpesu : opas EMA ensihoidon henkilökunnalle

open access: yes
Opinnäytetyössä tuotettiin opas ambulanssin oikeaoppisesta sisäpesusta. Opinnäytetyön yhteistyökumppanina toimi EMA ensihoito. Opinnäytetyön teoriaosuudessa käsitellään erilaisia tartuntatauteja ja niiden ehkäisyä hoitotyössä.
Gulmohammadi, Nima
core  

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden   +3 more
wiley   +1 more source

Unsafe action detection algorithm of underground personnel in coal mine based on YOLOv8

open access: yesMeitan kexue jishu
There are problems such as interference information, low illumination and mechanical equipment occlusion in the complex environment of underground coal mine, which makes the speed and accuracy of the existing object detection algorithm have a series of ...
Wei CHEN   +4 more
doaj   +1 more source

The EMAS Director [PDF]

open access: yesThe Computer Journal, 1975
openaire   +1 more source

Effects of ethyl 2-methyl acetoacetate (EMA) on the growth of Phaeodactylum tricornutum and Skeletonema costatum

open access: yes, 2012
We investigated the effects of ethyl 2-methyl acetoacetate (EMA) on growth of the marine diatom algae Phaeodactylum tricornutum (P. tricornutum) and Skeletonema costatum (S. costatum). Growth of P.
Yang, Cui Yun   +4 more
core   +1 more source

Through the lens of marketing authorization holders: experience in use of real‐world data and real‐world evidence in drug development and regulatory submissions in EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy